Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free VMD Stock Alerts

Viemed Healthcare (VMD) Financials

Viemed Healthcare logo
$9.52 +0.11 (+1.17%)
Closing price 04:00 PM Eastern
Extended Trading
$9.52 0.00 (-0.05%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Viemed Healthcare

Annual Income Statements for Viemed Healthcare

This table shows Viemed Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 9.51 8.53 32 9.13 6.22 10 11 15
Consolidated Net Income / (Loss)		 9.51 8.53 32 9.13 6.22 10 11 15
Net Income / (Loss) Continuing Operations		 9.51 8.53 32 9.13 6.22 10 11 15
Total Pre-Tax Income 		9.67 8.80 26 13 8.99 14 16 22
Total Operating Income		 10 8.86 27 12 8.25 14 18 23
Total Gross Profit		 48 56 80 73 85 113 133 155
Total Revenue		 64 80 131 117 139 183 224 270
Operating Revenue		 64 80 131 117 139 183 224 270
Total Cost of Revenue		 17 24 51 44 54 70 91 115
Operating Cost of Revenue		 17 24 51 44 54 70 91 115
Total Operating Expenses		 38 47 53 62 77 99 115 133
Selling, General & Admin Expense		 34 41 53 55 68 88 106 121
Research & Development Expense		 0.00 0.85 1.08 2.11 2.70 2.78 3.07 3.02
Depreciation Expense		 0.59 0.67 0.82 0.85 1.01 1.39 1.48 1.49
Other Operating Expenses / (Income)		 2.70 3.89 0.93 3.53 5.20 5.85 6.29 9.13
Other Special Charges / (Income)		 0.05 0.36 -2.33 0.45 0.35 0.65 -1.91 -2.24
Total Other Income / (Expense), net		 -0.39 -0.06 -0.42 0.92 1.73 0.16 -1.90 -0.93
Interest & Investment Income		 -0.18 -0.42 -0.42 0.92 0.74 0.06 -1.73 -1.18
Other Income / (Expense), net		 -0.21 0.36 - - 0.99 0.10 -0.17 0.25
Income Tax Expense		 0.16 0.27 -5.17 3.38 2.77 4.15 4.76 6.39
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - 0.00 0.00 0.14 0.44
Basic Earnings per Share		 $0.25 $0.23 $0.81 $0.23 $0.16 $0.27 $0.29 $0.38
Weighted Average Basic Shares Outstanding		 37.89M 37.72M 38.74M 39.49M 38.66M 38.35M 38.75M 38.90M
Diluted Earnings per Share		 $0.24 $0.21 $0.78 $0.22 $0.16 $0.25 $0.28 $0.37
Weighted Average Diluted Shares Outstanding		 39.68M 39.75M 40.53M 40.68M 39.81M 40.38M 40.81M 40.82M
Weighted Average Basic & Diluted Shares Outstanding		 - 38.49M 39.56M 39.68M 38.17M 38.76M 39.52M 38.60M

Quarterly Income Statements for Viemed Healthcare

This table shows Viemed Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 3.48 1.60 1.47 3.88 4.32 2.63 3.16 3.51 5.64 2.58 2.76
Consolidated Net Income / (Loss)		 3.48 1.60 1.48 3.91 4.42 2.71 3.25 3.60 5.82 2.71 2.90
Net Income / (Loss) Continuing Operations		 3.48 1.60 1.48 3.91 4.42 2.71 3.25 3.60 5.82 2.71 2.90
Total Pre-Tax Income 		5.08 2.12 2.25 5.50 6.31 3.66 4.96 5.14 8.01 3.99 4.05
Total Operating Income		 5.29 2.20 3.62 5.63 6.45 3.84 5.10 5.64 8.37 4.30 4.46
Total Gross Profit		 32 30 33 34 36 33 37 41 44 43 45
Total Revenue		 51 51 55 58 61 59 63 72 76 75 78
Operating Revenue		 51 51 55 58 61 59 63 72 76 75 78
Total Cost of Revenue		 19 21 22 24 25 26 26 31 32 33 33
Operating Cost of Revenue		 19 21 22 24 25 26 26 31 32 33 33
Total Operating Expenses		 27 28 29 29 32 30 32 36 36 39 41
Selling, General & Admin Expense		 24 25 27 27 28 28 29 32 32 35 37
Research & Development Expense		 0.65 0.75 0.76 0.76 0.80 0.80 0.85 0.78 0.60 0.58 0.50
Depreciation Expense		 0.43 0.42 0.38 0.35 0.34 0.35 0.35 0.40 0.39 0.39 0.39
Other Operating Expenses / (Income)		 1.53 1.43 1.62 1.71 1.52 2.31 2.34 2.18 2.30 2.45 2.03
Other Special Charges / (Income)		 0.27 0.21 - -0.47 - -2.37 -0.64 0.48 0.29 0.36 0.60
Total Other Income / (Expense), net		 -0.24 -0.06 -1.39 0.15 1.85 -0.10 -0.06 -0.46 -0.30 -0.27 -0.34
Interest Expense		 - - - - - 0.18 0.13 - - 0.31 0.25
Interest & Investment Income		 -0.21 -0.08 -1.37 -0.13 -0.15 - 0.00 -0.51 -0.36 - -0.16
Other Income / (Expense), net		 -0.03 0.03 -0.02 0.28 1.99 0.08 0.07 0.04 0.06 0.04 0.07
Income Tax Expense		 1.60 0.52 0.77 1.59 1.88 0.95 1.71 1.54 2.19 1.28 1.15
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 0.01 0.03 - 0.09 0.09 0.09 0.18 0.13 0.14
Basic Earnings per Share		 $0.09 $0.04 $0.04 $0.10 $0.11 $0.07 $0.08 $0.09 $0.14 $0.07 $0.07
Weighted Average Basic Shares Outstanding		 38.35M 38.72M 38.82M 38.87M 38.75M 39.43M 39.52M 38.64M 38.90M 38.43M 38.25M
Diluted Earnings per Share		 $0.08 $0.04 $0.04 $0.10 $0.10 $0.06 $0.08 $0.09 $0.14 $0.06 $0.07
Weighted Average Diluted Shares Outstanding		 40.38M 40.58M 40.55M 40.78M 40.81M 41.63M 41.08M 40.50M 40.82M 40.49M 41.13M
Weighted Average Basic & Diluted Shares Outstanding		 38.76M 38.82M 38.83M 38.94M 39.52M 39.52M 38.79M 38.02M 38.60M 38.34M 38.09M

Annual Cash Flow Statements for Viemed Healthcare

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 5.32 2.94 18 -2.57 -11 -4.08 4.70 -4.04
Net Cash From Operating Activities		 22 19 35 22 28 45 39 52
Net Cash From Continuing Operating Activities		 22 19 35 22 28 45 39 52
Net Income / (Loss) Continuing Operations		 9.51 8.53 32 9.13 6.22 10 11 15
Consolidated Net Income / (Loss)		 9.51 8.53 32 9.13 6.22 10 11 15
Depreciation Expense		 3.78 6.40 9.58 11 16 22 25 29
Amortization Expense		 - - - - 0.00 0.00 0.19 0.23
Non-Cash Adjustments To Reconcile Net Income		 9.16 14 4.20 12 4.27 6.77 5.61 6.89
Changes in Operating Assets and Liabilities, net		 -0.08 -9.64 -10 -9.68 1.62 6.34 -3.49 0.81
Net Cash From Investing Activities		 -5.30 -13 -8.42 -20 -24 -52 -31 -50
Net Cash From Continuing Investing Activities		 -5.30 -13 -8.42 -20 -24 -52 -31 -50
Purchase of Property, Plant & Equipment		 -6.11 -13 -13 -20 -23 -26 -39 -40
Acquisitions		 - - - - 0.00 -29 -3.00 -26
Sale of Property, Plant & Equipment		 0.81 0.57 5.26 0.60 1.06 2.59 10 16
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 0.75 0.00
Net Cash From Financing Activities		 -12 -3.33 -9.07 -5.32 -15 2.83 -3.69 -5.79
Net Cash From Continuing Financing Activities		 -12 -3.33 -9.07 -5.32 -15 2.83 -3.69 -5.79
Repayment of Debt		 0.00 0.00 -1.75 -4.00 -5.80 -11 -6.60 -14
Repurchase of Common Equity		 -1.59 -1.52 0.00 0.00 -9.57 0.00 0.00 -13
Payment of Dividends		 - - - - 0.00 0.00 -0.04 -0.37
Issuance of Debt		 0.00 9.38 - - 0.00 13 3.00 22
Other Financing Activities, net		 -10 -11 -7.32 -1.32 0.10 0.55 -0.05 -0.30
Cash Interest Paid		 0.19 0.33 0.56 0.35 0.23 0.85 0.95 0.87
Cash Income Taxes Paid		 0.15 0.34 3.31 1.77 -0.85 3.57 6.83 7.39

Quarterly Cash Flow Statements for Viemed Healthcare

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 2.76 -5.53 1.50 2.54 6.19 -7.38 9.86 -8.89 2.38 -3.74 0.92
Net Cash From Operating Activities		 13 1.18 10 13 15 2.85 12 18 18 8.07 16
Net Cash From Continuing Operating Activities		 13 1.18 10 13 15 2.85 12 18 18 8.07 16
Net Income / (Loss) Continuing Operations		 3.48 1.60 1.48 3.91 4.42 2.71 3.25 3.60 5.82 2.71 2.90
Consolidated Net Income / (Loss)		 3.48 1.60 1.48 3.91 4.42 2.71 3.25 3.60 5.82 2.71 2.90
Depreciation Expense		 5.92 6.29 6.31 6.41 6.37 6.61 6.89 7.54 7.57 7.62 7.52
Amortization Expense		 - 0.00 - 0.05 0.05 0.04 0.03 0.06 0.11 0.07 0.07
Non-Cash Adjustments To Reconcile Net Income		 1.86 1.57 2.25 1.37 0.42 -0.06 1.71 5.39 -0.14 2.81 2.79
Changes in Operating Assets and Liabilities, net		 2.03 -8.29 0.06 1.01 3.73 -6.45 0.38 1.79 5.09 -5.14 2.62
Net Cash From Investing Activities		 -7.49 -5.37 -11 -4.97 -9.20 -8.53 -1.73 -32 -7.61 -5.49 -7.84
Net Cash From Continuing Investing Activities		 -7.49 -5.37 -11 -4.97 -9.20 -8.53 -1.73 -32 -7.61 -5.49 -7.84
Purchase of Property, Plant & Equipment		 -7.95 -6.01 -8.93 -11 -13 -15 -8.13 -7.64 -8.74 -6.71 -8.46
Sale of Property, Plant & Equipment		 0.46 0.64 0.77 6.03 2.88 6.95 6.40 1.67 1.13 1.23 1.17
Net Cash From Financing Activities		 -3.03 -1.34 2.48 -5.24 0.40 -1.70 -0.67 5.04 -8.45 -6.33 -7.15
Net Cash From Continuing Financing Activities		 -3.03 -1.34 2.48 -5.24 0.40 -1.70 -0.67 5.04 -8.45 -6.33 -7.15
Repayment of Debt		 -2.94 -0.68 -0.62 -5.23 -0.16 -0.13 -0.12 -5.23 -8.41 -3.24 -2.18
Repurchase of Common Equity		 - - - - - 0.00 - -12 - -1.44 -5.32
Payment of Dividends		 - - - - - 0.00 - -0.09 -0.09 -0.17 -0.13
Other Financing Activities, net		 -0.09 -0.66 0.10 -0.00 0.60 -1.57 1.31 -0.08 0.05 -1.47 0.49
Cash Interest Paid		 0.35 0.22 0.29 0.23 0.21 0.13 0.09 0.38 0.29 0.23 0.16
Cash Income Taxes Paid		 0.35 0.00 3.84 2.58 0.41 2.96 4.10 0.21 0.12 0.01 0.36

Annual Balance Sheets for Viemed Healthcare

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 54 83 113 118 117 155 177 199
Total Current Assets		 23 28 47 47 40 38 53 48
Cash & Equivalents		 10 13 31 28 17 13 18 14
Accounts Receivable		 8.84 12 12 13 15 18 25 26
Inventories, net		 2.89 1.36 2.31 2.46 3.57 4.63 4.32 5.05
Prepaid Expenses		 0.95 1.56 1.51 1.73 3.85 2.45 6.11 4.13
Current Deferred & Refundable Income Taxes		 - - 0.00 1.89 0.03 - 0.00 0.23
Plant, Property, & Equipment, net		 31 55 0.00 0.00 68 74 76 79
Total Noncurrent Assets		 0.00 0.01 65 71 9.56 43 48 72
Long-Term Investments		 - 0.01 - - - 1.68 2.79 2.79
Goodwill		 - - - - 0.00 30 33 59
Intangible Assets		 - - - - 0.00 0.57 0.85 1.29
Noncurrent Deferred & Refundable Income Taxes		 - 0.00 8.73 4.79 3.12 4.56 8.40 5.29
Other Noncurrent Operating Assets		 0.00 0.00 57 66 6.44 5.98 2.83 3.58
Total Liabilities & Shareholders' Equity		 54 83 113 118 117 155 177 199
Total Liabilities		 21 39 31 23 20 41 44 56
Total Current Liabilities		 20 26 23 18 19 32 37 41
Short-Term Debt		 0.00 1.75 1.84 1.48 0.00 1.07 0.41 1.09
Accounts Payable		 5.88 4.70 2.10 3.24 2.65 4.18 5.32 7.33
Accrued Expenses		 7.55 8.97 13 8.88 11 18 20 24
Current Deferred Revenue		 2.59 3.32 3.41 3.75 4.62 6.21 6.69 7.52
Current Deferred & Payable Income Tax Liabilities		 0.15 0.09 0.34 - 0.00 2.15 3.88 0.00
Other Current Liabilities		 3.39 7.09 2.74 0.46 0.50 0.93 0.86 1.20
Total Noncurrent Liabilities		 1.51 13 7.85 5.33 1.09 8.88 6.44 15
Long-Term Debt		 0.00 7.63 5.80 4.31 0.00 6.00 3.59 11
Other Noncurrent Operating Liabilities		 1.51 5.36 2.05 1.03 1.09 2.87 2.85 3.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 33 44 82 95 97 114 133 144
Total Preferred & Common Equity		 33 44 82 95 97 114 131 142
Total Common Equity		 33 44 82 95 97 114 131 142
Common Stock		 5.46 9.74 17 22 27 34 42 39
Retained Earnings		 27 34 66 73 70 79 90 103
Noncontrolling Interest		 - - - - - 0.00 1.91 1.98

Quarterly Balance Sheets for Viemed Healthcare

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 125 149 149 155 164 170 178 185 202 197 204
Total Current Assets		 47 36 36 39 45 48 49 55 50 50 54
Cash & Equivalents		 24 10 10 7.31 8.81 11 10 20 11 9.76 11
Accounts Receivable		 16 18 18 24 27 27 27 27 27 31 32
Inventories, net		 3.45 4.48 4.67 4.35 4.42 4.31 4.51 4.32 5.27 5.18 5.27
Prepaid Expenses		 3.39 2.33 3.19 2.48 4.24 4.99 7.66 4.40 4.27 3.69 5.79
Current Deferred & Refundable Income Taxes		 0.00 1.03 0.00 - 0.45 - - - 1.91 0.00 0.00
Plant, Property, & Equipment, net		 68 73 73 74 75 74 81 80 81 76 77
Total Noncurrent Assets		 5.44 40 40 43 41 45 48 50 72 72 73
Long-Term Investments		 - - - - - - 2.79 2.79 2.79 2.79 3.18
Goodwill		 - 30 30 30 33 33 33 33 58 59 59
Intangible Assets		 - 0.69 0.69 0.53 0.91 0.88 0.82 0.78 1.35 1.22 1.16
Noncurrent Deferred & Refundable Income Taxes		 3.84 3.84 3.91 4.56 4.56 8.07 8.40 10 5.67 5.29 5.29
Other Noncurrent Operating Assets		 1.60 5.46 5.28 7.59 2.89 2.76 2.88 2.64 3.59 3.30 4.53
Total Liabilities & Shareholders' Equity		 125 149 149 155 164 170 178 185 202 197 204
Total Liabilities		 25 45 41 39 43 43 41 43 67 52 58
Total Current Liabilities		 23 32 32 30 31 36 35 37 44 41 48
Short-Term Debt		 - 3.17 1.83 0.60 0.77 0.81 0.39 0.82 1.55 0.87 0.72
Accounts Payable		 4.26 6.17 5.98 5.80 6.33 6.01 7.94 8.25 8.67 8.58 11
Accrued Expenses		 13 16 17 14 17 20 18 19 25 22 25
Current Deferred Revenue		 4.70 5.96 6.22 6.09 6.72 6.82 6.80 7.19 7.81 7.48 8.00
Current Deferred & Payable Income Tax Liabilities		 1.25 - 0.23 2.68 0.00 2.08 1.88 1.45 0.00 1.04 1.83
Other Current Liabilities		 0.40 0.77 0.58 0.90 0.85 0.81 0.94 0.91 1.15 1.20 1.42
Total Noncurrent Liabilities		 1.17 13 9.03 8.49 11 6.29 5.84 5.71 23 11 10
Long-Term Debt		 - 12 8.10 5.91 8.72 3.65 3.53 3.47 20 8.33 6.37
Other Noncurrent Operating Liabilities		 1.17 0.92 0.94 2.58 2.57 2.64 2.31 2.24 3.09 2.53 3.99
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 100 105 109 116 121 127 137 142 135 146 146
Total Preferred & Common Equity		 100 105 109 116 119 125 135 140 134 144 144
Total Common Equity		 100 105 109 116 119 125 135 140 134 144 144
Common Stock		 29 31 33 36 38 40 44 46 36 38 36
Retained Earnings		 71 73 76 80 82 85 91 94 97 105 108
Noncontrolling Interest		 - - - - 1.81 1.84 1.99 1.89 1.89 1.93 1.94

Annual Metrics And Ratios for Viemed Healthcare

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 37,952,660.00 39,145,182.00 39,630,446.00 - - - 38,017,907.00
DEI Adjusted Shares Outstanding		 0.00 37,952,660.00 39,145,182.00 39,630,446.00 - - - 38,017,907.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.22 0.81 0.23 - - - 0.39
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 24.50% 63.61% -10.85% 18.60% 31.82% 22.54% 20.52%
EBITDA Growth		 0.00% 14.54% 132.84% -37.05% 8.64% 45.91% 24.52% 20.24%
EBIT Growth		 0.00% -6.44% 190.56% -56.76% -20.20% 56.13% 36.07% 30.88%
NOPAT Growth		 0.00% -13.18% 273.13% -73.61% -32.43% 78.59% 23.83% 28.36%
Net Income Growth		 0.00% -10.34% 269.85% -71.06% -31.82% 64.63% 11.38% 34.77%
EPS Growth		 0.00% -12.50% 271.43% -71.79% -27.27% 56.25% 12.00% 32.14%
Operating Cash Flow Growth		 0.00% -14.67% 83.95% -35.93% 23.36% 62.94% -13.54% 32.81%
Free Cash Flow Firm Growth		 0.00% 0.00% 249.38% -140.32% 57.96% -607.71% 113.16% -404.12%
Invested Capital Growth		 0.00% 79.21% 46.93% 23.75% 11.06% 32.76% 9.88% 19.36%
Revenue Q/Q Growth		 0.00% 0.00% 8.02% 0.65% 4.16% 7.79% 4.65% 6.08%
EBITDA Q/Q Growth		 0.00% 0.00% 10.35% -1.37% 4.68% 10.33% 9.22% 3.56%
EBIT Q/Q Growth		 0.00% 0.00% 10.64% -4.94% -1.51% 14.74% 19.34% 2.35%
NOPAT Q/Q Growth		 0.00% 0.00% 8.19% -13.05% -19.10% 13.67% 7.77% 10.61%
Net Income Q/Q Growth		 0.00% 0.00% 9.30% -9.73% -20.95% 11.29% 9.05% 9.95%
EPS Q/Q Growth		 0.00% 0.00% 8.33% -8.33% -15.79% 4.17% 7.69% 12.12%
Operating Cash Flow Q/Q Growth		 0.00% -4.05% -4.38% 14.59% -3.38% 14.14% 4.56% 7.13%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 34.46% -372.31% 34.95% -32.73% 40.56%
Invested Capital Q/Q Growth		 0.00% 0.00% 14.85% 5.00% 6.92% -2.04% -0.24% -2.18%
Profitability Metrics		 - - - - - - - -
Gross Margin		 74.11% 69.78% 61.01% 62.71% 60.99% 61.63% 59.40% 57.52%
EBITDA Margin		 21.15% 19.46% 27.69% 19.56% 17.91% 19.83% 20.15% 19.25%
Operating Margin		 15.60% 11.04% 20.40% 9.89% 5.94% 7.83% 7.98% 8.49%
EBIT Margin		 15.28% 11.48% 20.40% 9.89% 6.66% 7.88% 8.75% 8.58%
Profit (Net Income) Margin		 14.75% 10.62% 24.01% 7.80% 4.48% 5.60% 5.09% 5.69%
Tax Burden Percent		 98.32% 96.92% 119.60% 72.99% 69.21% 71.18% 70.56% 70.64%
Interest Burden Percent		 98.16% 95.43% 98.44% 107.97% 97.28% 99.74% 82.37% 93.82%
Effective Tax Rate		 1.68% 3.08% -19.60% 27.01% 30.79% 28.82% 29.44% 29.36%
Return on Invested Capital (ROIC)		 44.62% 27.75% 65.33% 12.95% 7.50% 10.93% 11.31% 12.64%
ROIC Less NNEP Spread (ROIC-NNEP)		 48.27% 28.57% 68.99% 10.02% 4.91% 10.57% 21.57% 20.88%
Return on Net Nonoperating Assets (RNNOA)		 -15.43% -5.40% -15.04% -2.61% -1.01% -1.22% -2.08% -1.53%
Return on Equity (ROE)		 29.19% 22.35% 50.29% 10.34% 6.48% 9.71% 9.23% 11.11%
Cash Return on Invested Capital (CROIC)		 0.00% -28.99% 27.32% -8.28% -2.98% -17.22% 1.89% -5.01%
Operating Return on Assets (OROA)		 18.36% 13.53% 27.45% 10.05% 7.86% 10.61% 11.83% 12.33%
Return on Assets (ROA)		 17.72% 12.51% 32.31% 7.92% 5.30% 7.53% 6.87% 8.17%
Return on Common Equity (ROCE)		 29.19% 22.35% 50.29% 10.34% 6.48% 9.71% 9.16% 10.95%
Return on Equity Simple (ROE_SIMPLE)		 29.19% 19.51% 38.60% 9.62% 6.41% 8.99% 8.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 9.89 8.58 32 8.45 5.71 10 13 16
NOPAT Margin		 15.34% 10.70% 24.39% 7.22% 4.11% 5.57% 5.63% 6.00%
Net Nonoperating Expense Percent (NNEP)		 -3.64% -0.82% -3.66% 2.93% 2.58% 0.36% -10.27% -8.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - 5.88% 8.43% 9.20% 10.40%
Cost of Revenue to Revenue		 25.89% 30.22% 38.99% 37.29% 39.01% 38.37% 40.60% 42.48%
SG&A Expenses to Revenue		 53.32% 51.56% 40.23% 46.89% 49.10% 48.02% 47.36% 44.90%
R&D to Revenue		 0.00% 1.06% 0.82% 1.80% 1.94% 1.52% 1.37% 1.12%
Operating Expenses to Revenue		 58.51% 58.74% 40.61% 52.82% 55.76% 53.85% 52.19% 49.12%
Earnings before Interest and Taxes (EBIT)		 9.85 9.22 27 12 9.24 14 20 23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 14 16 36 23 25 36 45 52
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 5.38 3.72 2.18 2.96 2.65 2.38 2.00
Price to Tangible Book Value (P/TBV)		 0.00 5.38 3.72 2.18 2.96 3.62 3.20 3.47
Price to Revenue (P/Rev)		 0.00 2.93 2.31 1.77 2.07 1.65 1.39 1.05
Price to Earnings (P/E)		 0.00 27.60 9.63 22.67 46.20 29.50 27.72 18.91
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 3.62% 10.38% 4.41% 2.16% 3.39% 3.61% 5.29%
Enterprise Value to Invested Capital (EV/IC)		 0.00 5.83 4.81 2.55 3.37 2.77 2.55 2.01
Enterprise Value to Revenue (EV/Rev)		 0.00 2.88 2.14 1.57 1.95 1.61 1.33 1.04
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 14.81 7.71 8.05 10.88 8.12 6.59 5.39
Enterprise Value to EBIT (EV/EBIT)		 0.00 25.10 10.47 15.91 29.27 20.43 15.17 12.09
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 26.95 8.75 21.80 47.37 28.89 23.58 17.31
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 12.12 7.99 8.19 9.75 6.52 7.62 5.40
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 20.93 0.00 0.00 0.00 140.85 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.21 0.09 0.06 0.00 0.06 0.03 0.09
Long-Term Debt to Equity		 0.00 0.17 0.07 0.05 0.00 0.05 0.03 0.08
Financial Leverage		 -0.32 -0.19 -0.22 -0.26 -0.21 -0.12 -0.10 -0.07
Leverage Ratio		 1.65 1.79 1.56 1.31 1.22 1.29 1.34 1.36
Compound Leverage Factor		 1.62 1.70 1.53 1.41 1.19 1.29 1.11 1.28
Debt to Total Capital		 0.00% 17.67% 8.54% 5.75% 0.00% 5.85% 2.91% 7.94%
Short-Term Debt to Total Capital		 0.00% 3.30% 2.06% 1.47% 0.00% 0.89% 0.30% 0.70%
Long-Term Debt to Total Capital		 0.00% 14.37% 6.49% 4.28% 0.00% 4.96% 2.61% 7.24%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.39% 1.27%
Common Equity to Total Capital		 100.00% 82.33% 91.46% 94.25% 100.00% 94.15% 95.70% 90.79%
Debt to EBITDA		 0.00 0.60 0.21 0.25 0.00 0.19 0.09 0.24
Net Debt to EBITDA		 0.00 -0.26 -0.64 -0.99 0.00 -0.21 -0.36 -0.08
Long-Term Debt to EBITDA		 0.00 0.49 0.16 0.19 0.00 0.17 0.08 0.22
Debt to NOPAT		 0.00 1.09 0.24 0.68 0.00 0.69 0.32 0.76
Net Debt to NOPAT		 0.00 -0.46 -0.73 -2.68 0.00 -0.73 -1.29 -0.24
Long-Term Debt to NOPAT		 0.00 0.89 0.18 0.51 0.00 0.59 0.28 0.70
Altman Z-Score		 0.00 5.58 8.93 7.85 11.14 6.68 6.73 5.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.77% 1.40%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 1.18 1.07 2.05 2.66 2.11 1.19 1.42 1.18
Quick Ratio		 0.98 0.96 1.88 2.31 1.71 0.97 1.14 0.95
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.97 13 -5.40 -2.27 -16 2.11 -6.43
Operating Cash Flow to CapEx		 421.96% 148.99% 450.94% 113.92% 126.27% 192.19% 137.40% 217.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 1.20 1.18 1.35 1.02 1.18 1.35 1.35 1.44
Accounts Receivable Turnover		 7.29 7.88 10.99 9.29 9.85 10.82 10.34 10.70
Inventory Turnover		 5.78 11.42 27.90 18.31 17.96 17.12 20.35 24.52
Fixed Asset Turnover		 2.11 1.88 0.00 0.00 0.00 2.59 2.99 3.49
Accounts Payable Turnover		 2.84 4.58 15.07 16.36 18.39 20.56 19.17 18.15
Days Sales Outstanding (DSO)		 50.05 46.33 33.23 39.28 37.07 33.74 35.29 34.10
Days Inventory Outstanding (DIO)		 63.14 31.96 13.08 19.93 20.33 21.32 17.93 14.89
Days Payable Outstanding (DPO)		 128.69 79.65 24.23 22.30 19.85 17.75 19.04 20.11
Cash Conversion Cycle (CCC)		 -15.50 -1.36 22.08 36.91 37.55 37.30 34.18 28.87
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 22 40 58 72 80 106 117 140
Invested Capital Turnover		 2.91 2.59 2.68 1.79 1.82 1.96 2.01 2.11
Increase / (Decrease) in Invested Capital		 0.00 18 19 14 7.98 26 11 23
Enterprise Value (EV)		 0.00 231 280 184 271 295 298 281
Market Capitalization		 0.00 235 304 207 287 302 312 282
Book Value per Share		 $0.86 $1.15 $2.09 $2.39 $2.55 $2.96 $3.37 $3.72
Tangible Book Value per Share		 $0.86 $1.15 $2.09 $2.39 $2.55 $2.17 $2.51 $2.14
Total Capital		 33 53 89 101 97 121 137 156
Total Debt		 0.00 9.38 7.63 5.79 0.00 7.07 4.00 12
Total Long-Term Debt		 0.00 7.63 5.80 4.31 0.00 6.00 3.59 11
Net Debt		 -10 -3.99 -23 -23 -17 -7.45 -16 -3.91
Capital Expenditures (CapEx)		 5.30 13 7.79 20 22 24 28 24
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.89 -9.71 -4.99 2.57 3.97 -5.52 -1.58 -4.97
Debt-free Net Working Capital (DFNWC)		 3.52 3.65 26 31 21 7.32 16 8.53
Net Working Capital (NWC)		 3.52 1.90 24 29 21 6.24 16 7.44
Net Nonoperating Expense (NNE)		 0.38 0.06 0.50 -0.67 -0.51 -0.04 1.22 0.83
Net Nonoperating Obligations (NNO)		 -10 -3.99 -23 -23 -17 -7.45 -16 -3.91
Total Depreciation and Amortization (D&A)		 3.78 6.40 9.58 11 16 22 26 29
Debt-free, Cash-free Net Working Capital to Revenue		 -10.69% -12.09% -3.80% 2.20% 2.86% -3.02% -0.70% -1.84%
Debt-free Net Working Capital to Revenue		 5.46% 4.55% 19.80% 26.46% 15.04% 4.00% 7.12% 3.15%
Net Working Capital to Revenue		 5.46% 2.37% 18.40% 25.20% 15.04% 3.41% 6.94% 2.75%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.81 $0.23 $0.16 $0.27 $0.29 $0.38
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 38.74M 39.49M 38.66M 38.35M 38.75M 38.90M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.78 $0.22 $0.16 $0.25 $0.28 $0.37
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 40.53M 40.68M 39.81M 40.38M 40.81M 40.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 39.56M 39.68M 38.17M 38.76M 39.52M 38.60M
Normalized Net Operating Profit after Tax (NOPAT)		 9.94 8.93 17 8.78 5.95 11 13 15
Normalized NOPAT Margin		 15.42% 11.13% 13.04% 7.50% 4.29% 5.82% 5.63% 5.41%
Pre Tax Income Margin		 15.00% 10.96% 20.08% 10.68% 6.48% 7.86% 7.21% 8.05%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.32% 2.43%
Augmented Payout Ratio		 16.76% 17.85% 0.00% 0.00% 153.78% 0.00% 0.32% 88.44%

Quarterly Metrics And Ratios for Viemed Healthcare

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 39,521,618.00 39,523,787.00 38,785,759.00 38,017,907.00 38,602,631.00 38,336,802.00
DEI Adjusted Shares Outstanding		 - - - - - 39,521,618.00 39,523,787.00 38,785,759.00 38,017,907.00 38,602,631.00 38,336,802.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - 0.07 0.08 0.09 0.15 0.07 0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 35.28% 27.90% 26.91% 17.41% 19.62% 16.87% 14.72% 23.98% 25.51% 27.54% 23.85%
EBITDA Growth		 41.42% 25.65% 15.45% 20.94% 32.92% 24.06% 20.97% 7.44% 29.78% 13.76% 0.22%
EBIT Growth		 48.92% 10.67% 5.17% 39.02% 60.46% 75.61% 43.61% -3.69% 40.65% 10.60% -12.37%
NOPAT Growth		 50.70% 14.57% 7.63% 37.99% 24.96% 70.64% 40.25% -1.03% 34.31% 2.74% -4.28%
Net Income Growth		 42.62% 5.67% -36.61% 33.78% 27.24% 69.06% 120.04% -7.81% 31.46% 0.11% -10.77%
EPS Growth		 14.29% 0.00% -33.33% 42.86% 25.00% 50.00% 100.00% -10.00% 40.00% 0.00% -12.50%
Operating Cash Flow Growth		 72.88% -88.81% 33.57% -7.71% 12.82% 142.89% 20.35% 44.11% 23.05% 182.80% 29.77%
Free Cash Flow Firm Growth		 -306.01% -3,796.13% 77.18% 85.12% 73.56% 77.25% 90.22% -369.94% -176.59% -25.55% -1,751.74%
Invested Capital Growth		 32.76% 59.38% 8.67% 7.89% 9.88% 10.61% 3.39% 21.73% 19.36% 11.53% 13.07%
Revenue Q/Q Growth		 2.71% -0.29% 8.64% 5.53% 4.64% -2.58% 6.64% 14.05% 5.93% -1.01% 3.56%
EBITDA Q/Q Growth		 9.39% -23.85% 9.95% 32.04% 20.23% -14.90% 14.42% 9.89% 21.28% -25.40% 0.80%
EBIT Q/Q Growth		 23.92% -57.63% 36.91% 93.38% 43.04% -34.68% 31.95% 10.04% 48.29% -48.64% 4.55%
NOPAT Q/Q Growth		 25.09% -54.02% 42.82% 68.00% 13.27% -37.21% 17.38% 18.55% 53.72% -51.97% 9.35%
Net Income Q/Q Growth		 19.12% -53.90% -7.86% 164.39% 13.29% -38.74% 19.93% 10.77% 61.56% -53.35% 6.89%
EPS Q/Q Growth		 14.29% -50.00% 0.00% 150.00% 0.00% -40.00% 33.33% 12.50% 55.56% -57.14% 16.67%
Operating Cash Flow Q/Q Growth		 -3.80% -91.15% 766.55% 25.17% 17.59% -80.96% 329.36% 49.89% 0.40% -56.23% 97.03%
Free Cash Flow Firm Q/Q Growth		 26.42% -69.99% 82.78% 35.71% -30.76% -57.09% 92.59% -2,989.55% 23.04% 28.69% -9.22%
Invested Capital Q/Q Growth		 -2.04% 6.78% 3.12% -1.53% -0.24% 9.19% -3.61% 15.94% -2.18% 2.03% -2.28%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.29% 58.91% 59.84% 59.26% 59.54% 56.28% 58.25% 57.49% 57.89% 56.79% 57.68%
EBITDA Margin		 22.04% 16.83% 17.03% 21.31% 24.49% 17.87% 19.17% 18.47% 21.15% 15.94% 15.51%
Operating Margin		 10.42% 4.36% 6.58% 9.70% 10.63% 6.50% 8.08% 7.85% 10.99% 5.70% 5.71%
EBIT Margin		 10.37% 4.41% 5.55% 10.18% 13.91% 6.62% 8.19% 7.91% 11.07% 5.74% 5.80%
Profit (Net Income) Margin		 6.85% 3.17% 2.69% 6.73% 7.29% 4.58% 5.15% 5.01% 7.63% 3.60% 3.71%
Tax Burden Percent		 68.50% 75.58% 65.79% 71.01% 70.17% 74.00% 65.48% 70.11% 72.64% 67.98% 71.59%
Interest Burden Percent		 96.45% 95.11% 73.53% 93.14% 74.66% 93.51% 96.05% 90.31% 94.96% 92.15% 89.47%
Effective Tax Rate		 31.50% 24.42% 34.21% 28.99% 29.83% 26.00% 34.52% 29.89% 27.36% 32.02% 28.41%
Return on Invested Capital (ROIC)		 14.00% 6.80% 7.79% 13.07% 14.97% 9.20% 10.53% 10.78% 16.82% 8.22% 9.40%
ROIC Less NNEP Spread (ROIC-NNEP)		 15.20% 7.24% -53.47% 14.96% 15.84% 11.90% 11.36% 41.27% 19.43% 11.56% 11.72%
Return on Net Nonoperating Assets (RNNOA)		 -1.76% -0.95% -0.70% -0.62% -1.52% -0.46% -0.89% -0.37% -1.42% -0.51% -1.03%
Return on Equity (ROE)		 12.25% 5.85% 7.09% 12.46% 13.45% 8.74% 9.63% 10.42% 15.39% 7.71% 8.37%
Cash Return on Invested Capital (CROIC)		 -17.22% -34.71% 0.97% 2.78% 1.89% 1.28% 8.81% -8.32% -5.01% 1.15% 0.05%
Operating Return on Assets (OROA)		 13.96% 6.12% 7.30% 13.68% 18.80% 9.26% 11.33% 10.83% 15.90% 8.77% 8.99%
Return on Assets (ROA)		 9.22% 4.40% 3.53% 9.05% 9.85% 6.41% 7.12% 6.86% 10.97% 5.49% 5.76%
Return on Common Equity (ROCE)		 12.25% 5.85% 7.03% 12.36% 13.35% 8.67% 9.50% 10.27% 15.18% 7.60% 8.26%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 8.88% 7.94% 8.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.62 1.67 2.38 4.00 4.53 2.84 3.34 3.96 6.08 2.92 3.19
NOPAT Margin		 7.14% 3.29% 4.33% 6.89% 7.46% 4.81% 5.29% 5.50% 7.98% 3.87% 4.09%
Net Nonoperating Expense Percent (NNEP)		 -1.20% -0.44% 61.26% -1.89% -0.87% -2.69% -0.84% -30.48% -2.61% -3.35% -2.32%
Return On Investment Capital (ROIC_SIMPLE)		 2.99% - - - 3.30% 2.02% 2.29% 2.53% 3.90% 1.88% 2.09%
Cost of Revenue to Revenue		 36.71% 41.09% 40.16% 40.74% 40.46% 43.72% 41.75% 42.51% 42.11% 43.21% 42.32%
SG&A Expenses to Revenue		 47.11% 49.05% 48.22% 45.98% 46.48% 48.07% 45.68% 44.39% 42.29% 46.13% 47.55%
R&D to Revenue		 1.28% 1.48% 1.38% 1.31% 1.32% 1.35% 1.34% 1.08% 0.79% 0.77% 0.65%
Operating Expenses to Revenue		 52.81% 54.60% 52.24% 50.03% 52.19% 49.91% 50.29% 49.71% 46.98% 51.14% 52.06%
Earnings before Interest and Taxes (EBIT)		 5.26 2.23 3.05 5.90 8.45 3.92 5.17 5.69 8.43 4.33 4.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11 8.52 9.36 12 15 11 12 13 16 12 12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.65 3.14 2.13 2.28 2.38 2.14 1.95 1.97 2.00 2.47 3.03
Price to Tangible Book Value (P/TBV)		 3.62 4.25 2.98 3.12 3.20 2.85 2.58 3.57 3.47 4.25 5.21
Price to Revenue (P/Rev)		 1.65 1.88 1.24 1.33 1.39 1.24 1.13 1.03 1.05 1.24 1.45
Price to Earnings (P/E)		 29.50 35.38 26.86 27.30 27.72 23.42 19.54 19.35 18.91 23.88 30.14
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 3.39% 2.83% 3.72% 3.66% 3.61% 4.27% 5.12% 5.17% 5.29% 4.19% 3.32%
Enterprise Value to Invested Capital (EV/IC)		 2.77 3.16 2.14 2.37 2.55 2.20 2.08 1.91 2.01 2.49 3.11
Enterprise Value to Revenue (EV/Rev)		 1.61 1.88 1.24 1.30 1.33 1.21 1.06 1.07 1.04 1.24 1.43
Enterprise Value to EBITDA (EV/EBITDA)		 8.12 9.59 6.49 6.71 6.59 6.19 5.20 5.42 5.39 6.62 8.08
Enterprise Value to EBIT (EV/EBIT)		 20.43 24.90 17.24 16.88 15.17 14.46 11.21 12.02 12.09 14.99 18.81
Enterprise Value to NOPAT (EV/NOPAT)		 28.89 35.05 24.04 23.70 23.58 20.33 17.45 18.59 17.31 21.74 26.75
Enterprise Value to Operating Cash Flow (EV/OCF)		 6.52 10.16 6.63 7.43 7.62 6.88 5.99 5.62 5.40 6.20 7.11
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 230.58 88.35 140.85 180.22 24.05 0.00 0.00 227.09 6,949.88
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.06 0.06 0.08 0.04 0.03 0.03 0.03 0.16 0.09 0.06 0.05
Long-Term Debt to Equity		 0.05 0.05 0.07 0.03 0.03 0.03 0.02 0.14 0.08 0.06 0.04
Financial Leverage		 -0.12 -0.13 0.01 -0.04 -0.10 -0.04 -0.08 -0.01 -0.07 -0.04 -0.09
Leverage Ratio		 1.29 1.29 1.39 1.35 1.34 1.32 1.33 1.42 1.36 1.33 1.35
Compound Leverage Factor		 1.24 1.23 1.02 1.26 1.00 1.23 1.27 1.28 1.29 1.22 1.21
Debt to Total Capital		 5.85% 5.30% 7.26% 3.40% 2.91% 2.79% 2.94% 13.50% 7.94% 5.94% 4.63%
Short-Term Debt to Total Capital		 0.89% 0.49% 0.59% 0.62% 0.30% 0.28% 0.56% 0.99% 0.70% 0.56% 0.47%
Long-Term Debt to Total Capital		 4.96% 4.81% 6.67% 2.78% 2.61% 2.51% 2.37% 12.50% 7.24% 5.38% 4.16%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 1.38% 1.40% 1.39% 1.42% 1.30% 1.20% 1.27% 1.25% 1.26%
Common Equity to Total Capital		 94.15% 94.70% 91.36% 95.20% 95.70% 95.80% 95.77% 85.30% 90.79% 92.81% 94.10%
Debt to EBITDA		 0.19 0.17 0.24 0.11 0.09 0.09 0.09 0.42 0.24 0.17 0.13
Net Debt to EBITDA		 -0.21 -0.02 -0.03 -0.21 -0.36 -0.20 -0.38 0.14 -0.08 -0.06 -0.13
Long-Term Debt to EBITDA		 0.17 0.16 0.22 0.09 0.08 0.08 0.07 0.39 0.22 0.16 0.12
Debt to NOPAT		 0.69 0.62 0.89 0.38 0.32 0.28 0.29 1.44 0.76 0.57 0.44
Net Debt to NOPAT		 -0.73 -0.08 -0.11 -0.74 -1.29 -0.65 -1.26 0.49 -0.24 -0.21 -0.42
Long-Term Debt to NOPAT		 0.59 0.57 0.82 0.31 0.28 0.26 0.24 1.34 0.70 0.51 0.39
Altman Z-Score		 6.48 7.77 5.68 6.16 6.52 6.36 6.04 4.42 5.31 6.46 6.83
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.80% 0.78% 0.77% 0.79% 1.41% 1.42% 1.40% 1.39% 1.33%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.19 1.28 1.43 1.31 1.42 1.38 1.48 1.13 1.18 1.22 1.13
Quick Ratio		 0.97 1.06 1.20 1.10 1.14 1.04 1.25 0.87 0.95 1.01 0.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -23 -41 -7.12 -4.58 -5.99 -9.41 -0.70 -22 -17 -12 -13
Operating Cash Flow to CapEx		 177.47% 21.90% 124.66% 256.49% 150.65% 33.46% 709.55% 307.91% 242.26% 147.15% 218.25%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -52.55 0.00 0.00 0.00 -38.72 -52.01
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 15.94 0.00 0.00 0.00 26.46 64.12
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -31.71 0.00 0.00 0.00 8.48 34.74
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.35 1.39 1.31 1.34 1.35 1.40 1.38 1.37 1.44 1.53 1.55
Accounts Receivable Turnover		 10.82 9.51 9.15 9.53 10.34 9.08 8.99 9.36 10.70 9.89 10.26
Inventory Turnover		 17.12 19.36 18.05 18.96 20.35 21.70 22.95 22.40 24.52 25.08 26.75
Fixed Asset Turnover		 2.59 2.73 2.79 2.90 2.99 3.01 3.12 3.29 3.49 3.65 3.84
Accounts Payable Turnover		 20.56 15.00 12.85 14.21 19.17 13.99 13.76 14.62 18.15 14.72 13.34
Days Sales Outstanding (DSO)		 33.74 38.37 39.89 38.30 35.29 40.19 40.62 39.01 34.10 36.92 35.57
Days Inventory Outstanding (DIO)		 21.32 18.85 20.22 19.25 17.93 16.82 15.91 16.29 14.89 14.55 13.65
Days Payable Outstanding (DPO)		 17.75 24.33 28.40 25.69 19.04 26.10 26.52 24.96 20.11 24.80 27.37
Cash Conversion Cycle (CCC)		 37.30 32.89 31.71 31.86 34.18 30.91 30.00 30.34 28.87 26.67 21.84
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 106 115 119 117 117 128 123 143 140 142 139
Invested Capital Turnover		 1.96 2.07 1.80 1.90 2.01 1.91 1.99 1.96 2.11 2.12 2.30
Increase / (Decrease) in Invested Capital		 26 43 9.50 8.58 11 12 4.03 25 23 15 16
Enterprise Value (EV)		 295 365 255 278 298 281 256 272 281 354 432
Market Capitalization		 302 365 254 285 312 288 273 263 282 356 437
Book Value per Share		 $2.96 $3.00 $3.07 $3.22 $3.37 $3.41 $3.54 $3.44 $3.72 $3.73 $3.76
Tangible Book Value per Share		 $2.17 $2.22 $2.20 $2.35 $2.51 $2.55 $2.68 $1.90 $2.14 $2.17 $2.19
Total Capital		 121 123 131 131 137 141 146 157 156 155 153
Total Debt		 7.07 6.50 9.49 4.46 4.00 3.92 4.29 21 12 9.21 7.09
Total Long-Term Debt		 6.00 5.91 8.72 3.65 3.59 3.53 3.47 20 11 8.33 6.37
Net Debt		 -7.45 -0.81 -1.11 -8.68 -16 -9.03 -19 7.22 -3.91 -3.35 -6.77
Capital Expenditures (CapEx)		 7.49 5.37 8.17 4.97 9.95 8.53 1.73 5.97 7.61 5.49 7.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.52 1.79 3.67 -1.08 -1.58 3.86 -1.18 -3.78 -4.97 0.21 -3.89
Debt-free Net Working Capital (DFNWC)		 7.32 9.10 14 12 16 14 19 7.35 8.53 9.98 6.79
Net Working Capital (NWC)		 6.24 8.50 13 11 16 14 18 5.79 7.44 9.11 6.07
Net Nonoperating Expense (NNE)		 0.15 0.06 0.90 0.09 0.10 0.13 0.09 0.36 0.26 0.21 0.29
Net Nonoperating Obligations (NNO)		 -7.45 -0.81 -2.11 -9.55 -16 -9.03 -19 7.22 -3.91 -3.35 -6.77
Total Depreciation and Amortization (D&A)		 5.92 6.29 6.31 6.46 6.42 6.65 6.92 7.60 7.68 7.69 7.59
Debt-free, Cash-free Net Working Capital to Revenue		 -3.02% 0.92% 1.78% -0.50% -0.70% 1.66% -0.49% -1.48% -1.84% 0.07% -1.29%
Debt-free Net Working Capital to Revenue		 4.00% 4.69% 6.94% 5.63% 7.12% 6.02% 7.82% 2.88% 3.15% 3.48% 2.25%
Net Working Capital to Revenue		 3.41% 4.38% 6.56% 5.25% 6.94% 5.86% 7.48% 2.27% 2.75% 3.18% 2.01%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.09 $0.04 $0.04 $0.10 $0.11 $0.07 $0.08 $0.09 $0.14 $0.07 $0.07
Adjusted Weighted Average Basic Shares Outstanding		 38.35M 38.72M 38.82M 38.87M 38.75M 39.43M 39.52M 38.64M 38.90M 38.43M 38.25M
Adjusted Diluted Earnings per Share		 $0.08 $0.04 $0.04 $0.10 $0.10 $0.06 $0.08 $0.09 $0.14 $0.06 $0.07
Adjusted Weighted Average Diluted Shares Outstanding		 40.38M 40.58M 40.55M 40.78M 40.81M 41.63M 41.08M 40.50M 40.82M 40.49M 41.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.76M 38.82M 38.83M 38.94M 39.52M 39.52M 38.79M 38.02M 38.60M 38.34M 38.09M
Normalized Net Operating Profit after Tax (NOPAT)		 3.81 1.83 2.02 3.66 4.53 1.09 2.92 4.29 6.29 3.16 3.62
Normalized NOPAT Margin		 7.51% 3.61% 3.68% 6.32% 7.46% 1.84% 4.63% 5.96% 8.26% 4.19% 4.64%
Pre Tax Income Margin		 10.00% 4.19% 4.08% 9.48% 10.39% 6.19% 7.87% 7.14% 10.51% 5.29% 5.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 21.88 0.00 0.00 0.00 14.20 18.26
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 15.88 0.00 0.00 0.00 9.57 12.88
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -25.78 0.00 0.00 0.00 -3.78 -11.12
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -31.77 0.00 0.00 0.00 -8.41 -16.50
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.32% 0.00% 1.60% 2.30% 2.43% 3.56% 3.25%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.32% 0.00% 13.25% 96.88% 88.44% 98.91% 125.16%

Financials Breakdown Chart

Key Financial Trends

Viemed Healthcare (NASDAQ: VMD) has continued to grow revenue and generate positive earnings, although recent operating margins have softened and cash remains relatively modest compared with the company’s asset base. Revenue increased from $35.8 million in Q3 2022 to $78.1 million in Q2 2026. On a year-over-year basis, Q2 2026 revenue rose 23.8% from $63.1 million in Q2 2025.

Profitability has improved substantially over the longer term. Q2 2026 gross profit was $45.0 million, representing a 57.7% gross margin, compared with a 52.6% margin in Q2 2023. However, operating income of $4.5 million produced a 5.7% operating margin, below the 8.1% margin recorded in Q2 2025. Net income attributable to common shareholders was $2.8 million, or $0.07 per diluted share, compared with $3.2 million, or $0.08 per diluted share, in the year-ago quarter.

Cash generation remains a key strength. Operating cash flow increased to $15.9 million in Q2 2026 from $12.3 million in Q2 2025, and the company generated approximately $7.1 million of cash after net investing outflows. Viemed also reduced total debt to approximately $7.1 million at June 30, 2026, down from $9.2 million at March 31, 2026, although aggressive capital returns and equipment spending reduced the amount of cash retained on the balance sheet.

  • Strong multi-year revenue growth: Quarterly revenue climbed from $35.8 million in Q3 2022 to $78.1 million in Q2 2026, while Q2 2026 revenue grew 23.8% year over year.
  • Improved gross profitability: Gross margin was approximately 57.7% in Q2 2026, well above the roughly 52.6% margin reported in Q2 2023, indicating favorable long-term gross-profit expansion.
  • Consistent profitability: Viemed has reported positive net income in each of the supplied quarterly periods, with Q2 2026 net income attributable to common shareholders of $2.8 million.
  • Robust operating cash flow: Q2 2026 operating cash flow of $15.9 million was up from $12.3 million a year earlier and exceeded net capital spending by approximately $7.1 million.
  • Debt reduction: Total short- and long-term debt fell to about $7.1 million at the end of Q2 2026 from approximately $9.2 million at the end of Q1 2026.
  • Shareholder returns: The company repurchased $5.3 million of common stock and paid $133,000 in dividends during Q2 2026, which may support per-share value if repurchases are made at attractive prices.
  • Balance-sheet growth is driven partly by acquisitions and fixed assets: Total assets increased from $119.4 million in Q3 2022 to $204.2 million in Q2 2026, while goodwill reached $58.9 million. This creates potential for future growth but also increases the importance of acquisition performance and impairment monitoring.
  • Liquidity is positive but not excessive: Current assets of $54.0 million exceeded current liabilities of $47.9 million at June 30, 2026, implying a current ratio of approximately 1.13. Cash and equivalents totaled $10.7 million.
  • Operating margins have recently weakened: Q2 2026 operating income rose only modestly from $4.3 million in Q2 2025 to $4.5 million, despite stronger revenue. Selling, general and administrative expense increased to $37.1 million from $28.8 million.
  • Working-capital and capital-spending risks remain: Accounts receivable rose to $32.2 million, or roughly 41% of quarterly revenue, while Q2 capital purchases totaled $8.5 million. Continued investment and slower collections could pressure cash balances.

Overall, the statements show a company with strong top-line momentum, recurring profitability, improving operating cash flow and lower debt. The main risks for investors are the recent decline in operating margins, the sizable investment required to support growth, concentration of assets in goodwill and the relatively narrow cushion between current assets and current liabilities. Some prior-period income statement and cash flow figures were identified as restated in the supplied data, so historical comparisons should be interpreted with that qualification.

10/09/26 06:14 PM ETAI Generated. May Contain Errors.

Viemed Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Viemed Healthcare's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Viemed Healthcare had net income of $15.38 million at the end of 2025, a 34.8% increase from 2024, and a 61.7% increase since 2018. See Viemed Healthcare's forecast for analyst expectations on what's next for the company.

Viemed Healthcare's total operating income in 2025 was $22.95 million, based on the following breakdown:
  • Total Gross Profit: $155.46 million
  • Total Operating Expenses: $132.76 million

Over the last 7 years, Viemed Healthcare's total revenue changed from $64.46 million in 2018 to $270.28 million in 2025, a change of 319.3%.

In the past 13 quarters, Viemed Healthcare's cash and equivalents has ranged from $7.31 million in Q1 2024 to $23.54 million in Q1 2023, and is currently $10.68 million as of their latest financial filing in Q2 2026.

Viemed Healthcare had total debt of $12.38 million at the end of 2025, a 209.7% increase from 2024, and none in 2018.

Over the last 7 years, Viemed Healthcare's book value per share changed from 0.86 in 2018 to 3.72 in 2025, a change of 333.1%.


Related Companies

Financial statements for NASDAQ:VMD last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel